“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart
Article: P09 DARPin® molecule MP0250, a new antiangiogenic drug in multiple myeloma: An in vitro and in vivo study
P09 DARPin® molecule MP0250, a new antiangiogenic drug in multiple myeloma: An in vitro and in vivo study
Reviews
There are no reviews yet.
Be the first to review “Article: P09 DARPin® molecule MP0250, a new antiangiogenic drug in multiple myeloma: An in vitro and in vivo study” Cancel reply
Reviews
There are no reviews yet.